No Detail Found!

Emerging drug - resistance and guidelines for treatment of malatria.

Author(s)
M. Aslam Khan Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Raymond A. Smego Jr Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Syed Tabish Razi Department of Pharmaceutical Care, King Abdul Aziz Hospital, Al-Ahsa, Saudi Arabia
M. Asim Beg Department of Pathology and Microbiology, The Aga Khan University Hospital, Karachi, Pakistan
Abstract
The increasing prevalence of multi-Resistant Plasmodium falciparum malaria worldwide is a serious public health threat to the global control of malaria, especially in poor countries like Pakistan. In many countries choloroquine-resistance is a huge problem, accounting for more than 90% of cases. In Pakistan, resistance to choloroquin is on the rise and reported in up to 16-62% of plasmodium falciparum. Four to 25% of plasmodium falciparum also reported to be resistant to sulfadoxine-pyrimethamine and several cases of delayed parasite clearance have been observed in patients with plasmodium falciparum malaria treated with quinine. In this article we have introduced the concept of artemisinin-based combination therapy (ACT) and emphasize the use of empiric combination therapy for all patients with plasmodium falciparum malaria to prevent development of drug resistance and to obtain additive and synergistic killing of parasite.
Publication Details
Page(s) 319-324
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 14, Issue: 5, Year: 2004

Request the full text from PASTIC

0

Citations

0

Downloads

96

Views